229 related items for PubMed ID: 20196386
1. Final height of patients with classical congenital adrenal hyperplasia.
Aycan Z, Akbuğa S, Cetinkaya E, Ocal G, Berberoğlu M, Evliyaoğlu O, Adiyaman P.
Turk J Pediatr; 2009; 51(6):539-44. PubMed ID: 20196386
[Abstract] [Full Text] [Related]
2. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Völkl TM, Simm D, Beier C, Dörr HG.
Pediatrics; 2006 Jan; 117(1):e98-105. PubMed ID: 16396852
[Abstract] [Full Text] [Related]
3. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome.
Manoli I, Kanaka-Gantenbein Ch, Voutetakis A, Maniati-Christidi M, Dacou-Voutetakis C.
Clin Endocrinol (Oxf); 2002 Nov; 57(5):669-76. PubMed ID: 12390343
[Abstract] [Full Text] [Related]
4. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency.
Hauffa BP, Winter A, Stolecke H.
Klin Padiatr; 1997 Nov; 209(2):71-7. PubMed ID: 9113619
[Abstract] [Full Text] [Related]
5. The relation of peripubertal and pubertal growth to final adult height in children with classic congenital adrenal hyperplasia.
Bomberg EM, Addo OY, Kyllo J, Gonzalez-Bolanos MT, Ltief AM, Pittock S, Himes JH, Miller BS, Sarafoglou K.
J Pediatr; 2015 Mar; 166(3):743-50. PubMed ID: 25557963
[Abstract] [Full Text] [Related]
6. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation.
Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP.
J Clin Endocrinol Metab; 2009 Oct; 94(10):3882-8. PubMed ID: 19622620
[Abstract] [Full Text] [Related]
7. Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty.
Pijnenburg-Kleizen KJ, Thomas CMG, Otten BJ, Roeleveld N, Claahsen-van der Grinten HL.
J Pediatr Endocrinol Metab; 2019 Oct 25; 32(10):1055-1063. PubMed ID: 31573958
[Abstract] [Full Text] [Related]
8. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP.
J Clin Endocrinol Metab; 2007 May 25; 92(5):1635-9. PubMed ID: 17299071
[Abstract] [Full Text] [Related]
9. Effect of the dose of oral hydrocortisone on growth rate during long-term treatment of children with salt losing congenital adrenal hyperplasia.
Ciaccio M, Montiveros C, Rivarola MA, Belgorosky A.
Medicina (B Aires); 2002 May 25; 62(6):551-4. PubMed ID: 12532689
[Abstract] [Full Text] [Related]
10. Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens.
Rasat R, Espiner EA, Abbott GD.
N Z Med J; 1995 Aug 11; 108(1005):311-4. PubMed ID: 7644165
[Abstract] [Full Text] [Related]
11. HYDROCORTISONE THERAPY AND GROWTH TRAJECTORY IN CHILDREN WITH CLASSICAL CONGENITAL ADRENAL HYPERPLASIA.
Bizzarri C, Improda N, Maggioli C, Capalbo D, Roma S, Porzio O, Salerno M, Cappa M.
Endocr Pract; 2017 May 11; 23(5):546-556. PubMed ID: 28225306
[Abstract] [Full Text] [Related]
12. Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience.
Brunelli VL, Russo G, Bertelloni S, Gargantini L, Balducci R, Chiesa L, Livieri C, De Sanctis C, Einaudi S, Virdis R, Saggese G, Chiumello G.
J Pediatr Endocrinol Metab; 2003 Mar 11; 16 Suppl 2():277-83. PubMed ID: 12729404
[Abstract] [Full Text] [Related]
13. [Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: final height in 27 patients with the classical form].
Lemos-Marini SH, Guerra-Júnior G, Morcillo AM, Baptista MT, Silva LO, Maciel-Guerra AT.
Arq Bras Endocrinol Metabol; 2005 Dec 11; 49(6):902-7. PubMed ID: 16544012
[Abstract] [Full Text] [Related]
14. Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism.
Cordeiro GV, Silva IN, Goulart EM, Chagas AJ, Kater CE.
Arq Bras Endocrinol Metabol; 2013 Mar 11; 57(2):126-31. PubMed ID: 23525290
[Abstract] [Full Text] [Related]
15. Gender related differences in glucocorticoid therapy and growth outcomes among pubertal children with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH).
Deslauriers JR, Lenz AM, Root AW, Diamond FB, Bercu BB.
J Pediatr Endocrinol Metab; 2012 Mar 11; 25(9-10):977-81. PubMed ID: 23426829
[Abstract] [Full Text] [Related]
16. Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: growth pattern compared with genetic height potential.
Aycan Z, Ocal G, Berberoglu M, Cetinkaya E, Adiyaman P, Evliyaoglu O.
J Pediatr Endocrinol Metab; 2006 Mar 11; 19(3):245-51. PubMed ID: 16607925
[Abstract] [Full Text] [Related]
17. Overestimation of final height prediction in patients with classical congenital adrenal hyperplasia using the Bayley and Pinneau method.
Bonfig W, Schwarz HP.
J Pediatr Endocrinol Metab; 2012 Mar 11; 25(7-8):645-9. PubMed ID: 23155688
[Abstract] [Full Text] [Related]
18. Growth pattern and final height in 21-hydroxylase deficiency.
Bajpai A, Pandey RM, Kabra M, Menon PS.
Indian Pediatr; 2007 Oct 11; 44(10):771-3. PubMed ID: 17998577
[Abstract] [Full Text] [Related]
19. Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-the Minnesota cohort.
Sarafoglou K, Addo OY, Turcotte L, Otten N, Wickremasinghe A, Pittock S, Kyllo J, Lteif AN, Himes JH, Miller BS.
J Pediatr; 2014 May 11; 164(5):1141-1146.e1. PubMed ID: 24560184
[Abstract] [Full Text] [Related]
20. Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life.
Bonfig W, Schwarz HP.
Horm Res Paediatr; 2011 May 11; 75(4):264-8. PubMed ID: 21196707
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
